Postoperative pain relief after inguinalhernia operation ad modum Lichtenstein with net.
Conditions
Interventions
Trade Name: Marcain
Product Name: Marcain
Pharmaceutical Form: Solution for injection
Pharmaceutical form of the placebo: Injection*
Route of administration of the placebo: Infiltration use
Sponsors
Landstinget Västmanland, Division Kirurgi, Operationskliniken
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients, both male and female, that are undergoing daycare surgery for inguinal hernia (ad modum Lichtenstein) with a net implant. The patient has to be over 18 years of age and be able to accurately take in the given information and to understand and handle the infusor. The patient may not be excessively overweight, thus BMI should be =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: The patient may not be prescribed anticoagulants, with the excepiton of acetylsalicylic acid in low dose (75mg), or have any coagulopathy. The patient may not have been under medication on a daily basis with any other analgesic during the last three months. Females of fertile age will be asked if they are pregnant. Patients that are pregnant will be excluded. Patients with severe drugabuse. Pateints with BMI >35. Patients with any other comorbidity that will exclude them from daycare surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The main objective is to see wether a local anaesthetic, as eg Marcain, administered in a subcutaneous catheter in the operative wound area can diminish the postoperative pain and thereby reduce the use of other medication with adverse effects, as eg opioids. ;Secondary Objective: There is no secondary objective.;Primary end point(s): The number of opiod tablets needed to relieve the postoperative pain and hours after operation when first tablet is needed. | — |
Countries
Sweden
Outcome results
None listed